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Background: Pancreatic adenocarcinoma (PCA) is one of the most lethal human malignancies, and radical surgery
remains the cornerstone of treatment. After resection, the overall 5-year survival rate is only 10% to 29%. At the
time of presentation, however, about 40% of patients generally have distant metastases and another 40% are
usually diagnosed with locally advanced cancers. The remaining 20% of patients are indicated for surgery on the
basis of the results of preoperative imaging studies; however, about half of these patients are found to be
unsuitable for resection during surgical exploration. In the current study, we aimed to determine the
clinicopathological characteristics that predict the resectability of PCA and to conduct a prognostic analysis of PCA
after resection to identify favorable survival factors.
Methods: We retrospectively reviewed the medical files of 688 patients (422 men and 266 women) who had
undergone surgery for histopathologically proven PCA in the Department of Surgery at Chang Gung Memorial
Hospital in Taiwan from 1981 to 2006. We compared the clinical characteristics of patients who underwent
resection and patients who did not undergo resection in order to identify the predictive factors for successful
resectability of PCA, and we conducted prognostic analysis for PCA after resection.
Results: A carbohydrate antigen 19–9 (CA 19–9) level of 37 U/ml or greater and a tumor size of 3 cm or more
independently predicted resectability of PCA. In terms of survival after resection, PCA patients with better nutritional
status (measured as having an albumin level greater than 3.5 g/dl), radical resection, early tumor stage and better-
differentiated tumors were associated with favorable survival.
Conclusions: Besides traditional imaging studies, preoperative CA 19–9 levels and tumor size can also be used to
determine the resectability of PCA. Better nutritional status, curative resection, early tumor stage and well-
differentiated tumors predict the favorable prognosis of PCA patients after resection.Background
Pancreatic adenocarcinoma (PCA) is one of the most lethal
human malignancies and ranks as the eighth and ninth
most common causes of cancer-related mortality world-
wide for men and women, respectively [1]. In the United
States in 2008, 37,680 new cases of PCA were diagnosed,
and 34,290 PCA-related deaths occurred [2]. The inci-
dence-to-mortality ratio was nearly 1:1, illustrating the* Correspondence: yehchunnan@gmail.com
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reproduction in any medium, provided the orlethality of PCA. The overall 5-year survival rate of patients
with PCA is estimated to be approximately 1% to 4%, a
percentage range that is likely related to the aggressive
characteristics of PCA, such as early local spread and me-
tastasis and resistance to radiotherapy and most systemic
chemotherapies [3]. Currently, radical surgical resection is
the cornerstone of treatment. After resection, the overall 5-
year survival rate is only 10% to 29% [4-6]. However, previ-
ous studies have shown that, at the time of presentation,
about 40% of patients have distant metastases and another
40% are diagnosed with locally advanced cancers [2,3,7].
The remaining 20% of patients are indicated for surgery on
the basis of the results of preoperative imaging studies;Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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suitable for resection during surgical exploration [8-12].
Unnecessary surgical exploration may, in turn, lead to
increased surgical risk and healthcare costs and may delay
systemic treatment [13].
Therefore, accurate preoperative prediction of PCA
resectability is crucial to facilitating appropriate manage-
ment of PCA patients. In the past few years, researchers
have attempted to address this issue and have found that
preoperative measurement of carbohydrate antigen 19–9
(CA 19–9) level, endoscopic ultrasonography (EUS),
computed tomography (CT) and staging laparoscopy
may enhance the accuracy of prediction of resectability
before surgery [14-18].
Herein we retrospectively review the medical files of
688 PCA patients who underwent surgery at our hos-
pital from 1981 to 2006 and identified the predictive fac-
tors for resectability of PCA by comparing the clinical
characteristics of patients who underwent resection with
those of patients who did not undergo resection. Fur-
thermore, we also investigated the prognostic factors for
favorable PCA outcomes following resection.
Methods
We retrospectively reviewed the medical files of 688
patients who had undergone surgery for histopathologic-
ally proven PCA in the Department of Surgery at Chang
Gung Memorial Hospital in Taipei, Taiwan, from 1981
to 2006. This retrospective study was approved by the
local institutional review board of Chang Gung Memor-
ial Hospital (clinical study no. 94-955B).
Resection was defined as pancreatectomy (Whipple oper-
ation or distal pancreatectomy), regardless of the status of
pancreatic resection margin. The patients comprised 422
men and 266 women with a median age of 64 years (range,
14 to 93 years). Of these patients, 230 underwent resection
(the resection group), and the remaining 458 patients were
unable to undergo resection because of portal vein invasion
or carcinomatosis (the no-resection group). Surgical mor-
tality was defined as death within 1 month of surgery. La-
boratory tests were conducted 1 day before surgery. Serum
CA 19–9 and carcinoembryonic antigen (CEA) levels were
measured by radioimmunoassay. Tumors were preopera-
tively evaluated by abdominal ultrasonography, endoscopic
retrograde cholangiopancreatography (ERCP), percutan-
eous transhepatic cholangiography (PTC), CT, magnetic
resonance imaging with cholangiopancreatography (MRCP)
and angiography, as appropriate. Tumor stage was defined
according to the pathological tumor node metastasis
(pTNM) classification proposed by the Union for Inter-
national Cancer Control (UICC). Stages I and II represent
early-stage PCA, and stages III and IV represent advanced-
stage PCA. Patients with a tumoral resection margin or
lymph node metastasis were given adjuvant chemotherapyconsisting of a systemic 5-fluorouracil- or gemcitabine-
based regimen. Adjuvant radiotherapy was conducted
by intraoperative radiotherapy, external beam radiother-
apy and/or brachytherapy in patients with either a
positive section margin or local recurrence. The follow-
up period ranged from 1 to 169.4 months, and, during
follow-up, abdominal CT, chest X-ray, MRCP and
tumor marker measurement were performed as appro-
priate. In terms of tumor size, we chose 3 cm as the cut-
off value to investigate its impact on the resectablity of
pancreatic cancer based on our own experience.
Statistical analysis
All data are presented as the proportion (%) of patients
or as means with standard deviations. Numerical data
were compared using independent Student’s t-tests.
Nominal data were compared using Pearson’s χ2 test or
forward stepwise multiple logistic regression, as appro-
priate. Survival rates were calculated and plotted using
the Kaplan-Meier method. Clinicopathological variables,
including demographic data, laboratory data, clinical fea-
tures, pathological features and operative findings, were
selected for survival analysis. We performed survival
analysis using the logrank test and multivariate analysis
using the Cox proportional hazards model. All statistical
analyses were performed using the SPSS computer soft-
ware package (version 10.0; Chicago, IL, USA). A P-value
less than 0.05 was considered statistically significant.
Results
Survival of PCA patients
The median follow-up time for all patients in this study
was 6.5 months (range, 1 to 169.4 months). For the re-
section group, the median follow-up time was 13
months (range, 1 to 169.4 months) and, for the no-resec-
tion group, the median follow-up time was 4.9 months
(range, 1 to 65.7 months). Ninety-seven patients were
excluded from the survival analysis because of lack of
follow-up data or death within 1 month of surgery. The
overall 1-, 3- and 5-year survival rates for the remaining
591 PCA patients were 29.7%, 8.8% and 5.1%, respect-
ively. Patients in the resection group showed signifi-
cantly better survival than patients in the no-resection
group (Figure 1). The overall 3-year survival rate was
significantly higher in the resection group (22.6%) than
in the no-resection group (1.1%) (P < 0.0001). In
addition, the PCA resection rate has increased signifi-
cantly in our hospital over the past 3 decades, from, re-
spectively, 16% to 27.7% to 48.8% for 1981 to 1999, 1991
to 2000 and 2001 to 2006 (P < 0.0001).
Predictive factors for resectability of PCA
Table 1 summarizes the clinicopathological features of the
688 PCA patients. There were 230 patients in the resection
Figure 1 The difference of overall survival rates between 214 pancreatic cancer patients who underwent pancreatic resection and 377
pancreatic cancer patients who did not undergo pancreatic resection.
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mean age in the resection group was significantly lower
than that in the no-resection group (P = 0.047), and the re-
section group had a greater proportion of patients ages 65
years or younger (P = 0.015). The gender ratio in the
two groups was similar. No differences were observed
between the two groups with regard to preoperative
physical examination findings, but patients in the no-
resection group tended to be asymptomatic before the
operation (P = 0.018). Tumor distribution (head or of
the pancreas or not) was also similar in the two groups.
Patients in the resection group showed higher albumin
levels than those in the no-resection group (3.77 ± 0.65 g/dl
versus 3.63 ± 0.17 g/dl; P = 0.025). Furthermore, the pro-
portion of patients with albumin levels greater than 3.5 g/dl
in the resection group was higher than that in the no-
resection group (P = 0.02). The average of preoperative
aspartate aminotransferase (AST) level was higher in
the resection group than in the no-resection group. The
bilirubin levels were similar in both groups. With regard
to the serum levels of the tumor marker CA 19–9, we
found lower mean CA 19–9 levels in the resection
group than in the no-resection group, but the difference
was not statistically significant. In addition, the proportion
of patients with CA 19–9 levels above 37.0 U/ml in the no-
resection group was higher than that in the resection group(P = 0.007). Similarly, CEA levels were higher in the no-
resection group, and a higher proportion of patients in the
no-resection group had CEA levels greater than 5 ng/ml.
The mean tumor size in the no-resection group was 6.2 ±
3.5 cm, and that in the resection group was 4.61 ± 3.6 cm.
Because we had set 3 cm as the cutoff value for tumor size,
the no-resection group obviously showed a higher rate of
tumors over 3 cm than the resection group. Moreover, the
no-resection group had shorter operation times, fewer
postoperative complications and lower mortality rates than
the resection group did.
All significant predictive factors obtained in the univari-
ate analysis (Table 1) were included in our multivariate
analysis, which was performed using a logistic regression
method. Only CA 19–9 level <37 and tumor size <3 cm
were independent predictive factors for resectability of
PCA.
Factors influencing the survival of PCA patients after
resection
Univariate analysis (Table 2) indicated that women had a
better prognosis than men (P = 0.02), with overall 3- and
5-year survival rates of 29.9% and 23.1%, respectively, for
women and 3- and 5-year overall survival rates of 18.3%
and 8.6%, respectively, for men. An albumin level greater
than 3.5 g/dl was a favorable prognostic factor for survival
Table 1 Characteristics of pancreatic ductal
adenocarcinoma in patients with either resectable or
nonresectable tumors
Characteristics Resectable
tumor (n = 230)
Non-resectable
tumor (n = 458)
P value
Age (years) 62.1 ± 11.1 64.0 ± 12.0 0.047
<65 136 (59.1%) 226 (49.3%) 0.015
≥65 94 (40.9%) 232 (50.7%)
Sex 0.749
Male 143(62.2%) 279 (60.9%)
Women 87 (37.8%) 179 (37.1%)
Symptoms 0.018
Yes 225 (97.8%) 457 (99.8%)
No 5 (2.2%) 1 (0.2%)
Physical findings 0.979
Yes 166 (72.2%) 331 (72.3%)
No 64 (27.8%) 127 (27.7%)
Bilirubin (mg/dl) 7.5 ± 9.1 7.2 ± 8.5 0.574
≤1.3 80 (36.5) 177 (42.3) 0.155
>1.3 139 (63.5) 241 (57.7)
Albumin (g/dl) 3.77 ± 0.65 3.63 ± 0.71 0.025
≤3.5 61 (33.0%) 149 (43.3%) 0.020
>3.5 124 (67.0%) 195 (56.7%)
AST (U/L) 112.9 ± 146.8 84.8 ± 99.2 0.011
≤68 110 (49.1%) 250 (60.1%) 0.008
>68 114 (50.9%) 166 (39.9%)
CEA (ng/ml) 6.1 ± 8.1 13.5 ± 48.0 0.008
≤5 115 (67.6%) 180 (58.4%) 0.047
>5 55 (32.4%) 128 (41.6%)
CA 19–9 (U/ml) 1,229.6 ± 4,680.4 1,616.4 ± 5,253.1 0.425
≤37 48 (27.1%) 46 (16.5%) 0.007
>37 129 (72.9%) 232 (83.5%)
Operation time (minutes) 426.0 ± 155.3 219.2 ± 172.4 <0.0001
≤240 31 (13.9%) 285 (68.3%) <0.0001
>240 192 (86.1%) 132 (31.7%)
Complication 0.003
Yes 55 (23.9%) 67 (14.6%)
No 175 (76.1%) 391 (85.4%)
Death 0.017
Yes 7 (3.0%) 36 (7.6%)
No 223 (97.0%) 423 (92.4%)
Tumor size (cm) 4.6 ± 3.6 6.2 ± 3.5 <0.0001
≤3 94 (42.7%) 24 (15.8%) <0.0001
>3 126 (57.3%) 128 (84.2%)
Location 0.111
Head of pancreas 165 (71.7%) 301 (65.7%)
Not at head of pancreas 65 (28.3%) 157 (34.3%)
Table 1 Characteristics of pancreatic ductal
adenocarcinoma in patients with either resectable or
nonresectable tumors (Continued)
Differentiation 0.0002
Well 83 (36.1%) 134 (29.3%)
Moderate 105 (45.7%) 173 (37.8%)
Poor 35 (15.2%) 103 (22.5%)
Others 7 (3.0%) 48 (10.5%)
Post-op C/T <0.0001
Yes 121 (52.6%) 163 (35.6%)
No 109 (47.7%) 295 (64.4%)
Post-op R/T 0.255
Yes 17 (7.4%) 46 (10.0%)
No 213 (92.6%) 412 (90.0%)
AST: aspartate aminotransferase; CEA: carcinoembryonic antigen; CA 19–9:
carbohydrate antigen 19–9; Post-op C/T: postoperative chemotherapy; Post-op
R/T: postoperative radiotherapy; Others: mixed tumor differentiation.
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nontumoral resection margin, bilirubin levels of 1.3 mg/dl
or less, CA 19–9 levels of 37 U/ml or less, no lymph node
metastasis, early pTNM stage and well-differentiated
tumors, were also associated with a better prognosis. On
the other hand, age, preoperative physical examination
findings and preoperative biochemical data (including
levels of amylase, lipase and the tumor marker CEA) were
not associated with patient survival after resection of PCA.
Interestingly, we found that tumor location, operative pro-
cedure and portal vein resection were not related to patient
survival after PCA resection.
In the analysis of the significant factors using the multi-
variate Cox proportional hazards method, we identified al-
bumin levels greater than 3.5 g/dl (Figure 2a), nontumoral
resection margin (Figure 2b), well-differentiated tumors
(Figure 2c) and early pTNM stage (Figure 2d) as favorable
prognostic factors after resection of PCA.
Discussion
Pancreatic cancer ranks as the fifth most common cause
of cancer-related mortality worldwide, and patients with
PCA generally have a very poor prognosis [3]. Radical sur-
gical resection is the most effective treatment for PCA, be-
cause pancreatic tumors tend to respond poorly to both
radiotherapy and chemotherapy. According to the results
of previous studies, however, only 20% of PCA patients
are considered suitable for resection prior to surgical ex-
ploration, and during surgical exploration, half of these
patients are found to be unsuitable for resection because
of the advanced stage of the tumor [7].
Recent improvements in radiological imaging techni-
ques have decreased the rate of unnecessary surgical ex-
ploration; however, the current state of PCA resectability
Table 2 Univariate analysis of factors influencing the overall survival of the 214 PAC patients




1 year 3 years P-value
Age (years) 0.068
≤65 (130) 16.08 13.23 to 18.93 26.6 15.3
>65 (26) 10.28 9.05 to 11.53 16.8 12.0
Sex 0.020
Male (125) 11.18 8.51 to 13.85 18.3 8.6
Female (89) 16.57 14.05 to 19.09 29.9 23.1
Symptoms 0.007
Positive (209) 13.05 10.30 to 15.50 21.2 12.4
Negative (5) NA 80.0 80.0
Bilirubin (mg/dl) 0.009
≤1.3 (73) 17.39 12.19 to 22.59 26.7 26.9
>1.3 (130) 12.69 10.14 to 15.24 20.9 8.2
Albumin (g/dl ) 0.024
≤3.5 (54) 9.04 5.50 to 12.58 15.2 10.2
>3.5 (117) 15.75 12.45 to 19.05 25.4 16.7
Amylase (U/L) 0.216
≤300 (82) 13.05 8.77 to 17.33 19.3 13.4
>300 (12) 19.27 0.00 to 63.26 50.0 10.0
Lipase (U/L) 0.255
≤300 (47) 12.26 8.48 to 16.05 13.4 8.9
>300 (30) 16.04 6.03 to 26.05 26.7 16.0
CEA (ng/ml) 0.159
≤5 (109) 15.85 12.19 to 19.52 23.8 17.5
>5 (52) 10.42 7.04 to 13.80 24.7 6.1
CA 19–9 (U/ml) 0.044
≤37 (44) 19.43 8.50 to 30.37 32.6 22.3
>37 (125) 13.05 10.08 to 16.02 19.7 9.6
Surgical procedure 0.115
Whipple (119) 12.79 9.90 to 15.69 21.2 10.8
PPPD (39) 13.05 7.25 to 18.85 23.7 13.5
Others (56) 17.19 11.81 to 22.57 25.1 25.1
Resection margin (cm) 0.001
Nontumoral 15.42 13.12 to 17.72 58.8 27.3
Tumoral 9.67 8.15 to 11.19 42.1 10.5
Tumor location 0.096
Head (152) 12.79 10.34 to 15.24 21.3 11.12
Uncinate process (20) 19.13 3.79 to 34.47 32.8 32.8
Body (32) 19.27 9.75 to 28.80 22.7 22.7
Tail (10) 8.19 2.18 to 14.20 20.0 NA
Portal vein resection 0.249
Performed (12) 9.27 0.00 to 19.54 16.7 0.0
Not performed (202) 13.45 10.62 to 16.29 23.0 15.1
Tumor size (cm) <3 (90) 11.89 11.89 to 17.83 24.6 12.7 0.874
>3 (116) 8.02 8.02 to 16.30 21.9 14.5
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Table 2 Univariate analysis of factors influencing the overall survival of the 214 PAC patients (Continued)
Nodal status Negative (108) 18.87 14.04 to 23.70 34.0 23.1 <0.0001
Positive (105) 9.4 7.98 to 10.82 11.1 4.7
TNM staging I (32) 62.99 18.01 to 107.97 56.7 51.0 <0.0001
II (76) 15.78 12.77 to 18.79 24.9 12.3
III (106) 9.4 7.98 to 10.82 11.1 4.7
Tumor differentiation Well (76) 26.4 21.09 to 31.77 39.5 28.3 <0.0001
Moderate (98) 10.32 8.39 to 12.25 14.0 7.9
Poor (35) 9.47 5.67 to 13.27 12.1 3.0
Undifferentiated (5) 5.46 4.60 to 6.32 40.0 0.0
Post-op radiotherapy 0.849
Performed (17) 17.56 10.45 to 24.67 17.6 11.8
Not Performed (197) 12.79 9.79 to 15.80 23.1 14.3
Post-op chemotherapy
Performed (119) 14.93 11.70 to 18.16 22.7 10.4
Not Performed (95) 10.32 7.44 to 13.20 22.5 19.5
CEA: carcinoembryonic antigen; CA 19–9: carbohydrate antigen 19–9; NA: not applicable; TNM: tumor, node, metastasis; PPPD: pylorus preserving
pancreaticoduodenectomy.
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method of choice for diagnosing and staging PCA is thin-
section, contrast-enhanced, triple-phase CT [22,23]. This
method can result in a 90% to 100% predictive value for
the unresectability of PCA [14,24-26], but only a 52% to
96% predictive value for resectability has been reported
[8,11,24,27,28]. Other methods, such as EUS or 2-[18F]-
fluoro-2-deoxy-D-glucose positron emission tomog-
raphy (FDG-PET) is also unable to provide satisfactory
predictive value regarding resectablity before surgery
[16,29-32]. Taken together, these studies demonstrate
that no imaging studies can yet provide a complete picture
of the preoperative status of PCA to clinical physicians,
and thus further investigation of potential ancillary pre-
dictive factors is warranted.
In this study, we identified the clinicopathological fea-
tures of PCA patients that may be useful for predicting
the resectability of PCA. Physicians can use these ancil-
lary predictive factors, in combination with traditional
imaging studies, to determine the resectability of PCA
with increased accuracy.
In the current study, patients in the resection group
were, on average, 2 years younger than those in the no-
resection group (62 versus 64 years old; P = 0.047), and
the resection group comprised a greater proportion of
patients ages 65 years or younger (P = 0.015). This obser-
vation suggests that there may be a 2-year period during
which PCA progresses from being resectable to becoming
unresectable. We also found that CA 19–9 level 37 U/ml
or less and tumor size 3 cm or less were independent fac-
tors predicting the resectability of PCA. Furthermore,
patients in the resection group had longer operationtimes. The results of our study suggest that both CA
19–9 (≤37 U/ml) and tumor size (≤3 cm) could be used
as ancillary parameters to determine the resectability of
PCA (odds ratios, 2.458 and 3.155, respectively).
Serological markers of malignancy are widely used as
adjuncts to the results of imaging studies for diagnosing
malignancy and predicting prognosis. CA 19–9, initially
detected by Koprowaki et al. [33], is the most well-
established tumor marker for PCA, with higher sensitiv-
ity and specificity than CEA, CA 50, and CA 242
[34-36]. Some recent studies have emphasized the im-
portance of preoperative CA 19–9 levels in determining
the resectability of PCA [15,37]. Maithel et al. recom-
mended staging laparoscopy for patients whose CA 19–
9 levels exceeded 130.0 U/ml and who were diagnosed
with resectable PCA as indicated by radiography [17].
In our study, a lower percentage of patients in the resec-
tion group had preoperative CA 19–9 levels greater
than 37 U/ml, while CEA levels failed to independently
predict the resectability of PCA, an observation that is
in line with previous reports [34-36]. Although many
studies have investigated the relationship between
tumor size and prognosis in PCA [38-40], few studies
have associated tumor size with resectability. In the
current study, we found that tumor size (cutoff value, 3
cm) could be used to predict the resectability of PCA
independently.
For decades, researchers have attempted to determine
the factors predictive of favorable outcomes after resection
of PCA. In contrast to the study conducted by Schmidt
et al., our present study did not show that CEA level could
be used as a prognostic factor for PCA following tumor
Figure 2 The difference of overall survival rates between 214 pancreatic cancer patients undergoing pancreatic resection in terms of
(a) albumin, (b) resection margin status, (c) tumor differentiation and (d) tumor staging.
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reported findings similar to ours [38,42]. CA 19–9 level
has been widely reported to be a prognostic factor for
PCA after tumor resection [40,43,44]. Schmidt et al. [41]
also demonstrated that increased bilirubin predicted un-
favorable survival outcomes after PCA resection. In our
study CEA, however, neither CA 19–9 nor bilirubin inde-
pendently indicated a worse outcome after PCA resection.
Interestingly, in addition to well-established indicators of
survival, such as resection margin status, tumor stage and
histological differentiation, we identified serum albumin as
an independent prognostic factor after resection of PCA
in our study. Albumin has previously been shown to berelated to the prognosis of cancer patients [45,46]. In pan-
creatic cancer, Ruiz-Tovar et al. reported that the pre-
operative serum albumin level (with the cutoff value set at
2.8 g/dl) could be used as a prognostic factor for PCDA
[47]. Malnutrition has long been deemed a severe problem
involving complex mechanisms in cancer patients [48].
The lower serum albumin concentration in advanced can-
cer patients may be due to the release of some cytokines
such as interleukin 6 or TNF, to suppression of hepatocyte
production of albumin, or to increased capillary perme-
ability to albumin by the tumor or its surrounding tissues
[46,49]. For example, in conditions of liver metastasis
existing, Kupffer cells in the liver would be stimulated to
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bumin could be deemed a good indicator of cancer sur-
vival. In this study, albumin levels greater than 3.5 g/dl
were found to be associated with a better prognosis for
PCA survival after resection.
Conclusion
On the basis of our study results, we propose that pre-
operative CA 19–9 levels and tumor size less than 3 cm
can be used as auxiliary parameters, in combination with
traditional imaging studies, to determine the resectability
of PCA. Furthermore, albumin levels, resection margin sta-
tus, tumor stage and histological differentiation can be
used as prognostic factors for survival after resection of
PCA.
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